Sponsors (4)
The bill trades greater global coordination and faster development/deployment of pandemic tools—which can reduce outbreak risk and improve preparedness—for higher taxpayer costs, potential delays or conflicts in domestic access and oversight, and risks of regulatory complexity and equity disputes.
Urban and rural communities, patients, and health systems will face lower risk of domestic outbreaks because stronger international collaboration and U.S. coordination speed detection, development, and deployment of pandemic products and prioritize access to designated high‑priority countermeasures.
U.S. armed forces and local/state governments benefit from improved partner‑country public‑health capacity and surveillance that reduce cross‑border spread and limit readiness disruptions to deployed personnel.
Federal health agencies, Congress, state governments, and health systems gain clearer criteria for which pathogens and products trigger reporting and oversight, improving coordination and more timely prioritization of response resources.
Taxpayers could face higher federal spending or resource reallocation to support international capacity‑building, coordination, and joint funding arrangements without guaranteed domestic payoff.
Patients (especially those with chronic conditions and seniors) and health systems risk delayed domestic access to scarce countermeasures if emphasis on international sharing, equitable access, or commercialization priorities diverts supplies or favors profitable products over less‑profitable public‑health needs.
Hospitals and responders could be disadvantaged if tying action to predefined 'priority pathogen' lists delays recognition and response to newly emerging threats that are not yet listed.
Based on analysis of 4 sections of legislative text.
Requires State (with HHS) to deliver an 18‑month federal strategy to secure international arrangements to develop, commercialize, and equitably deploy pandemic/epidemic products, including for antimicrobial‑resistant pathogens.
Official title: To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
Introduced March 9, 2026 by Mike Levin · Last progress March 9, 2026
Requires the Secretary of State, working with HHS and other agencies, to produce and submit to Congress within 18 months a federal strategy to secure international arrangements that accelerate development, commercialization, equitable access, and deployment of qualified pandemic or epidemic products — including those targeting antimicrobial‑resistant pathogens. The strategy must describe processes for partnerships and contracts, stewardship and allocation, regulatory and reimbursement pathways, strengthening partner‑country public‑health capacity, and alignment with existing U.S. preparedness strategies. Directs the State Department, in consultation with HHS and other agencies, to pursue arrangements with foreign governments, multilateral organizations, and other entities to implement that strategy; defines key terms including which pathogens and products qualify and which congressional committees receive the documents.